Medpace Holdings, Inc. MEDP
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +18.13%
- 1 year
- +11.69%
- Market cap
- 18.56B
- Revenue (ttm)
- 2.84B
- Profit margin
- 18.24%
- EPS (ttm)
- 18.01
- Shares out
- 27.97M
- P/E ratio
- 36.84
- Forward P/E
- 33.42
- YTD return
- +18.13%
- 1-year return
- +11.69%
- Volume
- 229.52K
- Avg volume
- 257.43K
- Open
- 648.80
- Previous close
- 648.14
- Day's range
- 648.26 – 673.25
- 52-week range
- 373.00 – 693.97
- Beta
- 1.11
- Analysts
- Hold
- Price target
- 651.31 (-1.8%)
- Earnings date
- Feb 8, 2027
2Y +345.53 (+108.67%)
Key statistics
- Enterprise value
- 17.60B
- PEG ratio
- 3.33
- Price / sales
- 6.54
- Price / book
- 31.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 8.50%
- Free cash flow
- 497.78M
- Total cash
- 705.32M
- Total debt
- 171.46M
- Return on equity
- 117.88%
- Short % of float
- 7.19%
- 50-day average
- 619.67
- 200-day average
- 529.52
Analyst view
Consensus: hold
- Target (low)
- 370.00
- Target (mean)
- 651.31
- Target (high)
- 730.00
- Strong buy1
- Buy1
- Hold11
- Sell1
- Strong sell0
Next earnings
Feb 8, 2027
Expected Feb 8, 2027. Consensus EPS estimate 4.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 8, 2027 | Dec 30, 2026 | 4.82 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 4.44 | 4.84 | +0.40 | +9.01% |
| Jul 22, 2026 | Jun 30, 2026 | 3.98 | 4.25 | +0.27 | +6.78% |
| Apr 22, 2026 | Mar 31, 2026 | 3.92 | 4.28 | +0.36 | +9.18% |
| Feb 9, 2026 | Dec 31, 2025 | 4.19 | 4.67 | +0.48 | +11.46% |
| Oct 22, 2025 | Sep 30, 2025 | 3.53 | 3.86 | +0.33 | +9.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Oct 23, 2026 | UBS | main | Neutral | Neutral |
| Oct 23, 2026 | Truist Securities | main | Hold | Hold |
| Oct 23, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 23, 2026 | TD Cowen | main | Hold | Hold |
| Oct 7, 2026 | Mizuho | main | Outperform | Outperform |
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- medpace.com
News
CON vs. MEDP: Which Stock Is the Better Value Option? 
Medpace (MEDP) is a Great Momentum Stock: Should You Buy? 
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run? 
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes" 
BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $670 
All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy 
Here's Why Medpace (MEDP) is a Strong Growth Stock 
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate 
UBS Maintains Neutral on Medpace Holdings, Raises Price Target to $700 
Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $633
Your note
Sign in to keep a note on MEDP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY KEVIN M. | Chief Financial Officer | Sale | Aug 19, 2026 | 12,830 |
| BURWIG SUSAN ELIZABETH | Officer | Sale | Oct 26, 2026 | 54,012 |
| CARLEY BRIAN T | Director | Sale | Aug 18, 2026 | 27,825 |
| DAVENPORT FRED B JR | Director | Sale | Aug 18, 2026 | 5,798 |
| EWALD STEPHEN P | General Counsel | Sale | Oct 28, 2026 | 19,098 |
| GEIGER JESSE J | President | Sale | Mar 16, 2026 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 2,498,248 | 1.66B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 7.40% | 2,069,677 | 1.37B | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.57% | 1,278,935 | 848.56M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.05% | 1,133,357 | 751.97M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.67% | 1,026,820 | 681.28M | Jun 29, 2026 |
| State Street Corporation | 2.54% | 710,895 | 471.67M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.88% | 805,328 | 534.33M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.59% | 724,942 | 480.99M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.87% | 523,659 | 347.44M | Jun 29, 2026 |
| T. Rowe Price Equity Funds, Inc.-T. Rowe Price Large-Cap Growth Fund | 1.35% | 376,363 | 249.71M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Quality ETF | 1.18% | 329,256 | 218.46M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.08% | 302,065 | 200.42M | Jun 29, 2026 |